• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem Inc (NQ: VSTM )

    3.990 -0.140 (-3.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Verastem Inc

    < Previous 1 2 3 4 Next >
    Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Participate in Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants
    From Verastem Oncology
    Via Business Wire
    Bragar Eagel & Squire, P.C. Is Investigating Verastem, Helios, and LegalZoom and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
    From Verastem Oncology
    Via Business Wire
    VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
    From Kirby McInerney LLP
    Via Business Wire
    Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
    From Verastem Oncology
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.